Multiple Sclerosis News Today: Stem Cell Institute MS Trial is #4 in Top 10 MS Stories of 2018

Image of Top 10 Banner

Congratulations to Dr. Riordan and everyone at Stem Cell Institute and Medistem Labs in Panama!

Multiple Sclerosis News Today published its Top 10 Multiple Sclerosis Stories of 2018 and named Stem Cell Institute’s MS clinical trial its #4 top MS story of 2018.

From the article:

Multiple Sclerosis News Today brought you daily coverage of key findings, treatment developments, and clinical trials related to multiple sclerosis (MS) throughout 2018.

We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2019.

Here are the top 10 most-read articles of 2018, with a brief description of what made them relevant for the MS community.

No. 4 — “Treatment with Umbilical Cord Stem Cells Safe with Sustained Benefits for MS, Trial Shows”

Results of a Phase 1/2 clinical trial (NCT02034188) showed that treatment with mesenchymal stem cells (MSCs) collected from the umbilical cord led to sustained  lessening of disability in MS patients. The team at the Stem Cell Institute, in Panama, recruited 20 MS patients, 15 of whom had relapsing-remitting MS. All received seven intravenous infusions of 20×106 cells over one week. Besides easing disability —  particularly at one month of treatment — the stem cells improved hand function and average walk time, while lessening bladder, bowel, and sexual dysfunction. No serious adverse side effects were found. The patients also reported improved quality of life. Fifteen of 18 patients showed inactive brain lesions one year after the treatment; one had almost complete elimination of lesions. At the same one-year evaluation, the team found that the reduced disability was sustained.

The post Multiple Sclerosis News Today: Stem Cell Institute MS Trial is #4 in Top 10 MS Stories of 2018 appeared first on Stem Cell Institute.